Austar Lifesciences Ltd.

As of December 31, 2025, Austar Lifesciences Ltd. carries a market capitalization of 445.95M, placing it among publicly traded companies globally. Its enterprise value stands at 577.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Austar Lifesciences Ltd. has 512.58M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Austar Lifesciences Ltd. maintains a current ratio of 1.36, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Austar Lifesciences Ltd.'s stock has declined approximately 46.55% over the past 52 weeks. The 50-day moving average sits at 0.70, while the 200-day moving average is 0.78.

As of December 31, 2025, Austar Lifesciences Ltd. holds 253.06M in cash and equivalents against 382.47M in total debt, resulting in a net debt position of 104.87M. Total book value stands at 915.40M, with working capital of 473.69M providing operational flexibility.